Simplex P Bone Cement
The Foundation of a Successful Implant
In 1971, Stryker Simplex P Bone Cement revolutionized orthopaedics. Two years later, the product was approved for total knee surgery, and in 1976 for use in pathological fractures and general prosthetic fixation. In 2003, Simplex P with Tobramycin became one of the first cleared antibiotic-impregnated bone cement in the United States. Simplex P SpeedSet, a faster-setting version of Stryker’s original formula, was released in 2006. For more than 40 years, Simplex P Bone Cement, combined with the Stryker cement delivery system, has earned the trust and confidence of tens of thousands of surgeons. Countless articles in respected, peer-reviewed journals confirm its performance.1-3
Features & Benefits
At the heart of the Simplex P Bone Cement family of products’ enduring history is the science behind its success - a unique chemical composition that has become the orthopaedic standard by which other bone cements are measured. Simplex P provides the right ingredients in the right formula to balance unrivaled strength4 with consistent handling for excellent intraoperative and long-term results.1-3
1. US Markets for Reconstructive Implants. Millennium Research Group, May 2005.
2. Fish DN, Hoffman HM, Danziger LH. Antibiotic-impregnated cement use in US hospitals. Am J Hosp Pharm. 1992;49: 2469-2474.
3. Nijhof M, Dhert W, Tillman P, Verbout A, Fleer A. Release of tobramycin-containing bone cement in bone and serum of rabbits. J Mat Sci Mat Med. 1997;8(12):342–353.
4. Sterling GJ, Potter JM, Koerbin G, Crawford S, Crawford R, 2002. The pharmacokinetics of Simplex P Tobramycin Bone Cement. A study investigating the elution characteristics of Simplex P Tobramycin Bone Cement in total hip replacement. J Bone Joint Surg (Br) 2003; 85-B:646-9.
5. Physicians Desk Reference Edition 54, Medical Economics Company, Inc. Montvale NJ. 2000; 1628-1631.